Greg Moeck, PhD

Vice President, Microbiology
Venatorx Pharmaceuticals
Malvern, Pennsylvania, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 731 - CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

  Thursday, October 20, 2022
  2:00 PM – 2:15 PM US ET